

Date: Tuesday, October 14, 2025 **Time:** 12:00 PM - 1:00 PM

Location: Virtual Conference Room **Learning Format:** Live Activity

Presentation Information:

- Hematology and Oncology: Genitourinary (GU) Multidisciplinary Tumor Board & Palliative Care
 - Hematology and Oncology: Genitourinary (GU) Multidisciplinary Tumor Board & Palliative Care -10/14/2025

Description:

Hematology and Oncology: Genitourinary (GU) Multidisciplinary Tumor Board & Palliative Care Series Objectives:

- 1 Acquire knowledge of and skill in genitourinary malignancies, palliative care and quality of life through discussion of case-based examples.
- 1 Apply palliative care to advanced cancer cases.
- 2 Implement new treatment strategies in GI Tumors/ Disease/ Cancer and recognize opportunities to improve patient centered care.
- 3 Recognize and improve patient centered care designed to implement new treatment strategies in GI malignancies.
- 5 Cite the rationale for the management of patients with genitourinary malignancies discussed at this conference.
- 6 Discuss management of localized and metastatic prostate cancer, localized and metastatic bladder cancer, and advanced renal cell carcinoma.
- 7 Describe management of localized and metastatic prostate cancer, penile cancer, testicular cancer, metastatic bladder cancer, and advanced renal cell carcinoma.
- 8 Incorporate considerations for palliative care in patients with genitourinary malignancies.

Accreditation Statement:

University of California, Davis Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation:

UC Davis Health designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 Credit^m. Physicians should claim only the credit commensurate with the extent of their participation in the activity. UC Davis Health designates this live activity for a maximum of 1.00 Participation Hour(s).

Mitigation Statement:

University of California, Davis Health Continuing Medical Education adheres to the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

Disclosures:

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Shelley Palumbo, MS, SLP	Activity Administrator	Nothing to disclose - 09/18/2025
Mamta Parikh, MD	Course Director	Advisor-Bicycle Therapeutics (Relationship has ended) Advisor-Exelixis, Inc. (Relationship has ended) Advisor-Bristol-Myers Squibb Company (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etcPfizer (Any division) (Relationship has ended) Grant or research support-Karyopharm (Relationship has ended) Other: Steering Committee Member-Totus Medicines - 02/18/2025
Richard Valicenti, MD	Course Director	Nothing to disclose - 12/18/2024
Jared M Whitson, MD	Faculty	Nothing to disclose - 07/01/2025

Commercial Support:

This activity is not commercially supported.